SOA Wealth Advisors’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

SOA Wealth Advisors’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-150	Closed	-$2.24K	–	878
2024 Q3	$2.24K	Hold	150	–	–	﹤0.01%	660
2024 Q2	$2.03K	Hold	150	–	–	﹤0.01%	672
2024 Q1	$2.49K	Hold	150	–	–	﹤0.01%	682
2023 Q4	$2.02K	Hold	150	–	–	﹤0.01%	697
2023 Q3	$1.64K	Hold	150	–	–	﹤0.01%	733
2023 Q2	$1.94K	Hold	150	–	–	﹤0.01%	727
2023 Q1	$1.8K	Hold	150	–	–	﹤0.01%	742
2022 Q4	$2.06K	Hold	150	–	–	﹤0.01%	735
2022 Q3	$2K	Hold	150	–	–	﹤0.01%	700
2022 Q2	$2K	Hold	150	–	–	﹤0.01%	689
2022 Q1	$2K	Buy	150 +11	+8%	+$209	﹤0.01%	787
2021 Q4	$3K	Hold	139	–	–	﹤0.01%	719
2021 Q3	$4K	Hold	139	–	–	﹤0.01%	704
2021 Q2	$4K	Hold	139	–	–	﹤0.01%	685
2021 Q1	$4K	Hold	139	–	–	﹤0.01%	642
2020 Q4	$4K	Buy	+139	New	+$4.17K	﹤0.01%	625

Other funds holding CNCR

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BBPWM

Blue Bell Private Wealth Management Blue Bell, Pennsylvania $696M AUM 17.73% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

SOA Wealth Advisors's CNCR Position: Q4 2024 in Review

SOA Wealth Advisors sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q4 2024, closing a stake of 150 shares — an estimated $2.24K sold.

SOA Wealth Advisors first reported a position in CNCR in Q4 2020 and held it in 16 quarters. The position peaked at $4K in Q3 2021. 11 funds tracked by Wall St. Rank hold CNCR as of Q4 2024.

SOA Wealth Advisors reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q4 2024 after selling out during the quarter.
SOA Wealth Advisors sold 150 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q4 2024, an estimated $2.24K.
SOA Wealth Advisors first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2020 and held it in 16 quarters.
SOA Wealth Advisors's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $4K in Q3 2021.
11 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q4 2024.

Based on SOA Wealth Advisors's 13F filing for Q4 2024, filed 28 Jan 2025.